SA
CATX icon

Scarborough Advisors’s Perspective Therapeutics CATX Stock Holding History

Scarborough Advisors’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11
Closed -$130 – 452
2024
Q1 		$130 Buy
+11
New +$94 ﹤0.01% 395

Other funds holding CATX

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Scarborough Advisors's CATX Position: Q2 2024 in Review

Scarborough Advisors sold out of Perspective Therapeutics (CATX) in Q2 2024, closing a stake of 11 shares — an estimated $130 sold.

Scarborough Advisors first reported a position in CATX in Q1 2024 and held it in 1 quarter. The position peaked at $130 in Q1 2024. 105 funds tracked by Wall St. Rank hold CATX as of Q2 2024.

  • Scarborough Advisors reported no remaining Perspective Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Scarborough Advisors sold 11 Perspective Therapeutics shares in Q2 2024, an estimated $130.
  • Scarborough Advisors first reported a position in Perspective Therapeutics in Q1 2024 and held it in 1 quarter.
  • Scarborough Advisors's Perspective Therapeutics position peaked at $130 in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2024.

Based on Scarborough Advisors's 13F filing for Q2 2024, filed 8 Aug 2024.